TransMedics Group Financial Statements
NASDAQ: TMDXHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
TransMedics Group revenue and earnings
In fiscal 2025, TransMedics Group generated $605.5 million in revenue, up 37.1% from fiscal 2024, its 7th consecutive year of revenue growth. Net income was $190.3 million (+436.6% year over year), for a net margin of 31.4% versus a median of -38.8% in the prior 5 years. Gross margin was 59.9% (up from 59.4%) and operating margin 17.9%.
Diluted earnings per share came in at $4.87, up from $1.01. Over the last 5 fiscal years, TMDX's revenue has grown at a 88.2% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
TransMedics Group income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-28 | FY 20182018-12-29 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 605.49M | 441.54M | 241.62M | 93.46M | 30.26M | 25.64M | 23.60M | 13.02M |
| Revenue growth (YoY) | +37.13% | +82.74% | +158.53% | +208.83% | +18.03% | +8.62% | +81.33% | — |
| Cost of Revenue | 242.69M | 179.46M | 87.53M | 28.19M | 9.10M | 9.00M | 9.74M | 7.28M |
| Gross Profit | 362.81M | 262.08M | 154.09M | 65.27M | 21.16M | 16.64M | 13.86M | 5.73M |
| Operating Expenses | 254.22M | 224.59M | 182.82M | 96.71M | 60.59M | 43.02M | 43.47M | 25.97M |
| Research & Development | 69.06M | 55.97M | 36.05M | 26.81M | 22.30M | 18.83M | 19.87M | 13.66M |
| Selling, General & Admin | 185.17M | 168.62M | 119.55M | 69.90M | 38.28M | 24.19M | 23.60M | 12.31M |
| Operating Income | 108.58M | 37.50M | -28.73M | -31.44M | -39.43M | -26.38M | -29.60M | -20.24M |
| Interest Expense | 13.78M | 14.41M | 10.79M | 3.73M | 3.87M | 3.98M | 4.35M | 2.72M |
| Other Income (Expense) | -1.06M | -1.72M | 2.06M | -4.73M | -4.75M | -2.33M | -3.90M | -3.48M |
| Pretax Income | 107.52M | 35.78M | -26.67M | -36.16M | -44.18M | -28.72M | -33.51M | -23.71M |
| Income Tax | -82.77M | 316.00K | -1.64M | 66.00K | — | 0 | 0 | 0 |
| Net Income | 190.29M | 35.46M | -25.03M | -36.23M | -44.22M | -28.75M | -33.55M | -23.76M |
| Net Income growth (YoY) | +436.58% | — | — | — | — | — | — | — |
| EPS (Basic) | 5.60 | 1.07 | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -17.48 |
| EPS (Diluted) | 4.87 | 1.01 | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -17.48 |
| Shares Outstanding (Basic) | 33.99M | 33.23M | 32.52M | 29.56M | 27.62M | 24.70M | 14.20M | 1.36M |
| Shares Outstanding (Diluted) | 40.54M | 35.22M | 32.52M | 29.56M | 27.62M | 24.70M | 14.20M | 1.36M |
| EBITDA | 135.77M | 57.25M | -20.55M | -27.96M | -37.61M | -24.81M | -28.38M | -19.47M |
| Gross Margin | 59.92% | 59.36% | 63.77% | 69.84% | 69.92% | 64.88% | 58.73% | 44.05% |
| Operating Margin | 17.93% | 8.49% | -11.89% | -33.64% | -130.29% | -102.91% | -125.42% | -155.47% |
| Net Margin | 31.43% | 8.03% | -10.36% | -38.77% | -146.11% | -112.13% | -142.12% | -182.50% |
This table shows 8 annual periods of TransMedics Group's income statement, from FY 2025 back to FY 2018, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow TMDX's reporting calendar. What is a income statement?